INT232417

Context Info Confidence 0.04 First Reported 2007 Last Reported 2007 Negated 0 Speculated 0 Reported most in Body Documents 1 Total Number 2 Disease Relevance 0.99 Pain Relevance 0.86

mitochondrion (Mtx1)

Mtx1 (Mus musculus) Ifx (Mus musculus)

Pain Link Frequency Relevance Heat Infliximab 156 100.00 methotrexate 12 100.00 rheumatoid arthritis 112 87.76 Pain scale 2 71.96 Arthritis 4 44.00 spinal inflammation 2 43.16 imagery 10 5.00 cINOD 4 5.00 withdrawal 2 5.00 Inflammation 2 5.00

Disease Link Frequency Relevance Heat Disease 58 98.04 Disease Progression 4 92.80 Rheumatoid Arthritis 112 87.76 Frailty 4 80.80 Pain 4 71.72 Arthritis 4 44.00 Low Back Pain 2 43.16 Infection 6 5.00 Lymphatic System Cancer 4 5.00 Mycobacterial Infection 4 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

The largest double blind RCT, the ASPIRE trial (St Clair et al 2004), included 1049 patients, and compared the effect of methotrexate-IFX (MTX-IFX) with MTX-placebo on clinical, radiological, and functional scores at 1 year.

MTX Binding (effect) of methotrexate-IFX associated with infliximab and methotrexate

1) Confidence 0.04 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376089 Disease Relevance 0.41 Pain Relevance 0.50

Overall, the results of the different RCTs comparing MTX-IFX with MTX alone indicate that improvements on measures of disease activity are relatively modest.

MTX Binding (comparing) of IFX associated with infliximab and disease

2) Confidence 0.04 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376089 Disease Relevance 0.59 Pain Relevance 0.36

General Comments

This test has worked.